Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Leigh Ann Boyle"'
Autor:
Elaine M Walsh, Ayca Gucalp, Sujata Patil, Marcia Edelweiss, Dara S Ross, Pedram Razavi, Shanu Modi, Neil M Iyengar, Rachel Sanford, Tiffany Troso-Sandoval, Mila Gorsky, Jackie Bromberg, Pamela Drullinsky, Diana Lake, Serena Wong, Patricia DeFusco, Nicholas Lamparella, Ranja Gupta, Tasmila Tabassum, Leigh Ann Boyle, Artavazd Arumov, Tiffany A Traina
Publikováno v:
Cancer Research. 82:P1-14
Background: Chemotherapy remains the mainstay of treatment for early-stage triple negative breast cancer (TNBC), yet targetable drivers of interest are under investigation. A subset of TNBCs express the androgen receptor (AR) and exhibit androgen-dep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c13cb51455eb77d7eedf06d84d46453
https://doi.org/10.1158/1538-7445.sabcs21-p1-14-03
https://doi.org/10.1158/1538-7445.sabcs21-p1-14-03
Autor:
Elaine M. Walsh, Ayca Gucalp, Sujata Patil, Marcia Edelweiss, Dara S. Ross, Pedram Razavi, Shanu Modi, Neil M. Iyengar, Rachel Sanford, Tiffany Troso-Sandoval, Mila Gorsky, Jacqueline Bromberg, Pamela Drullinsky, Diana Lake, Serena Wong, Patricia Ann DeFusco, Nicholas Lamparella, Ranja Gupta, Tasmila Tabassum, Leigh Ann Boyle, Artavazd Arumov, Tiffany A. Traina
Publikováno v:
Breast cancer research and treatment. 195(3)
Chemotherapy with or without immunotherapy remains the mainstay of treatment for triple-negative breast cancer (TNBC). A subset of TNBCs express the androgen receptor (AR), representing a potential new therapeutic target. This study assessed the feas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e2e3c8d641ff0c1453658b5161f94ac
https://pubmed.ncbi.nlm.nih.gov/35986801
https://pubmed.ncbi.nlm.nih.gov/35986801
Autor:
Patricia DeFusco, Tiffany A. Traina, Ayca Gucalp, Nicholas Lamparella, Mark E. Robson, Tina Alano, Victoria S. Blinder, Sujata Patil, Jessica M. Scott, Artavazd Arumov, Leigh Ann Boyle, Lee W. Jones
Publikováno v:
Cancer Research. 80:P5-12
BACKGROUND: A subset of TNBC expresses a luminal signature and demonstrates AR-dependence. Enzalutamide (ENZA), an AR-antagonist, has activity with metastatic AR+ TNBC, with a clinical benefit rate of 33% (Traina et al, JCO 2018). We recently demonst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb9ef567198ca24ce54a3cddc491ce31
https://doi.org/10.1158/1538-7445.sabcs19-p5-12-09
https://doi.org/10.1158/1538-7445.sabcs19-p5-12-09
Autor:
Tiffany A. Traina, Kimberly Feigin, Clifford A. Hudis, S. Patil, Adriana D. Corben, Ayca Gucalp, Leigh Ann Boyle
Publikováno v:
Cancer Research. 77:P2-08
This abstract was withdrawn by the authors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::150bcda8700ecf28121e750ea12a0111
https://doi.org/10.1158/1538-7445.sabcs16-p2-08-05
https://doi.org/10.1158/1538-7445.sabcs16-p2-08-05
Autor:
Marcia Edelweiss, Tina Alano, Sujata Patil, Louise Ligresti, Mrinal M. Gounder, Artavazd Arumov, Leigh Ann Boyle, Kimberly Feigin, Gabriella D'Andrea, Jacqueline Bromberg, Ayca Gucalp, Serena Tsan-Lai Wong, Tiffany A. Traina, Shari Goldfarb
Publikováno v:
Journal of Clinical Oncology. 38:1017-1017
1017 Background: Genome-wide transcriptional analysis has identified a unique subset of androgen receptor (AR) +, estrogen receptor (ER)/progesterone receptor (PR)- breast cancer (BC). The functional role of AR was confirmed initially in preclinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abc9b4691e2607210437557cf0ef033b
https://doi.org/10.1200/jco.2020.38.15_suppl.1017
https://doi.org/10.1200/jco.2020.38.15_suppl.1017
Autor:
Rachel Ann Sanford, Artavazd Arumov, Patricia DeFusco, Leigh Ann Boyle, Ayca Gucalp, Marcia Edelweiss, Shanu Modi, Tiffany A. Traina, Sujata Patil, Nicholas Lamparella, Mila Gorsky
Publikováno v:
Journal of Clinical Oncology. 37:546-546
546 Background: A subset of TNBC is dependent on AR signaling. Enzalutamide (ENZA), an AR-antagonist, has activity in patients (pts) with metastatic AR+ TNBC, with a clinical benefit rate of 33%. This study tests the feasibility of adjuvant ENZA for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3999c1dbd5f1cd432c364d5eea39e99d
https://doi.org/10.1200/jco.2019.37.15_suppl.546
https://doi.org/10.1200/jco.2019.37.15_suppl.546
Autor:
Adriana D. Corben, S. Patil, Ayca Gucalp, Clifford A. Hudis, Leigh Ann Boyle, Tiffany A. Traina
Publikováno v:
Annals of Oncology. 27:vi81
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28c6c895e545bdbb3858a0baeb70acbb
https://doi.org/10.1093/annonc/mdw365.40
https://doi.org/10.1093/annonc/mdw365.40
Autor:
Adriana D. Corben, Mary Ellen Moynahan, Sujata Patil, Clifford A. Hudis, Tiffany A. Traina, Tracy Ann Proverbs-Singh, Leigh Ann Boyle, Ayca Gucalp
Publikováno v:
Journal of Clinical Oncology. 34:TPS1103-TPS1103
TPS1103Background: Patients (pts) with triple negative breast cancer (TNBC) have limited effective therapeutic options and generally experience a more aggressive clinical course. Emerging evidence demonstrates that the androgen-signaling pathway play
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43af3d98f1292f9308b9e8b497c2daa5
https://doi.org/10.1200/jco.2016.34.15_suppl.tps1103
https://doi.org/10.1200/jco.2016.34.15_suppl.tps1103